Active Ingredient(s): Encorafenib
FDA Approved: * June 27, 2018
Category: Cancer

* This drug may consist of multiple approval dates, manufacturers, or distributors. If applicable, they would be listed below under "NDC Database Records".

Braftovi Overview

Encorafenib (trade name Braftovi) is a drug for the treatment of certain melanomas. It is a small molecule BRAF inhibitor [1] that targets key enzymes in the MAPK signaling pathway. This pathway occurs in many different cancers including melanoma and colorectal cancers.[2] The substance was being developed by Novartis and then by Array BioPharma. In June 2018, it was approved by the FDA in combination with binimetinib for the treatment of patients with unresect...

Read more Braftovi Details
Details May Include Instructions, Side Effects, Interactions, Etc. Drug monograph is from Wikipedia. All text is available under the terms of the GFDL (GNU Free Documentation License). Source:

Recent Braftovi Forums:

Be the first to start a discussion about this drug.

Possible Dosages for this and Related Drugs:

  • Capsule: 50mg, 75mg
Note: Above list includes dosages for all drugs with the same combination of active ingredients.

NDC Database Records for Braftovi: (2 results)

Sorted by National Drug Code
  • 70255-020 Braftovi 50 mg Oral Capsule by Array Biopharma Inc.
  • 70255-025 Braftovi 75 mg Oral Capsule by Array Biopharma Inc.

Other drugs which contain Encorafenib or a similar ingredient: (1 result)